

**SUBMITTAL TO THE BOARD OF SUPERVISORS
COUNTY OF RIVERSIDE, STATE OF CALIFORNIA**

126



FROM: Riverside County Regional Medical Center (RCRMC)

SUBMITTAL DATE:
December 20, 2011

SUBJECT: Professional Services Agreement for Specialized Pathology Services with Esoterix Genetic Laboratories, LLC.

RECOMMENDED MOTION: Move that the Board of Supervisors:

- 1) Approve and authorize the Chairman of the Board to sign the Professional Services Agreement with Esoterix Genetic Laboratories, LLC to provide specialized pathology testing services effective the date of final execution and continue in effect for twelve (12) months, with an option to renew annually up to four (4) additional one-year terms not to exceed the aggregate amount of \$370,000 annually, and;
- 2) Authorize the Purchasing Agent, in accordance with Ordinance No. 459, to sign amendments that do not change the substantive terms of the agreement and allow the Purchasing Agent to increase the total compensation not more than 10% should the need for services exceed the estimated volume.

Douglas D. Bagley

Douglas D. Bagley, Hospital Director

| | | | | |
|-----------------------|-------------------------------|-----------|-------------------------|-----------|
| FINANCIAL DATA | Current F.Y. Total Cost: | \$370,000 | In Current Year Budget: | Yes |
| | Current F.Y. Net County Cost: | \$ 0 | Budget Adjustment: | No |
| | Annual Net County Cost: | \$ 0 | For Fiscal Year: | 2011/2012 |

| | | |
|--|---|--------------------------|
| SOURCE OF FUNDS: 100% Hospital Enterprise Funds | Positions To Be Deleted Per A-30 | <input type="checkbox"/> |
| | Requires 4/5 Vote | <input type="checkbox"/> |

C.E.O. RECOMMENDATION: APPROVE

BY: *Debra Cournoyer*
Debra Cournoyer

County Executive Office Signature

Consent Policy
 Consent Policy

Dept Recomm.:
 Per Exec. Ofc.:

Prev. Agn. Ref.: 02/03/04, 3.13; 09/2/04, 3.36; 08/09/05, 3.34; (CONT'D PAGE 2) **District:** ALL **Agenda Number:**

ATTACHMENTS FILED WITH THE CLERK OF THE BOARD

3.21

FORM APPROVED BY COUNTY COUNSEL
 BY: *Neal R. Denis*
 DATE: 12/21/12
 Departmental Concurrence
 Purchasing: *Mark Seiler*, Assistant Director

SUBJECT: Professional Services Agreement for Specialized Pathology Services with Esoterix Genetic Laboratories, LLC.

PREVIOUS AGENDA REFERENCE: 07/25/06, 3.42; 07/31/07, 3.86; 07/29/08, 3.113; 09/27/11, 3.24

BACKGROUND:

Riverside County Regional Medical Center (RCRMC) has contracted with Esoterix Genetic Laboratories, LLC. (formerly known as, Genzyme Genetics, Inc.) since February, 2004 providing specialize surgical pathology testing and consultation used in the treatment of cancer and leukemia. LabCorp completed its acquisition of Genzyme Genetics as of December 1, 2010, through LabCorp's wholly-owned subsidiary, Esoterix Genetic Laboratories, LLC.

Esoterix's current contract agreement ended June 30, 2011, with no additional renewal options remaining. On September 27, 2011; Agenda Item 3.24, the Board approved a six-(6) month (180 days) extension to the current contract with Esoterix to continue services until a Request for Proposal (RFP) for specialized surgical pathology consult and testing services was completed and a new contract was awarded.

In September, 2011, County Purchasing released RFP MCARC170, to secure specialized pathology testing services for the hospital. Solicitations were sent to at least three (3) prospective vendors specializing in this service and advertised on the County's Internet/Website. County Purchasing received one bid from Esoterix Genetic Laboratories, LLC. The bid was reviewed by three professional hospital staff based on the bidder's overall responsiveness to the RFP requirements, the effectiveness of the proposal, the geographical area, the background and experience of the bidder, and the overall cost were thoroughly evaluated.

After a review and evaluation of the proposal, Esoterix was determined as the single source & most responsible/responsive vendor. Esoterix Genetic Laboratories, LLC is the only supplier within the geographic area that provides the expertise and combined services required to provide expert diagnostic pathology services for the hospital. Other laboratories outside of the area are not able to provide these services due to the timeframe necessary to deliver and process specimens. Therefore, the Hospital Director requests the Board to approve the abovementioned motions.

PRICE REASONABLENESS:

As a result of RFP MCARC170 and even after the change of company ownership, Esoterix's fee schedule/billing rates remain the same and consistent with the current fiscal year's fee schedule.

FINANCIAL IMPACT:

100% Hospital Enterprise Funds

REVIEW/APPROVAL:

County Purchasing
County Counsel

DB:ns

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

This Agreement is made and entered into by and between the County of Riverside, a political subdivision of the State of California, through its Medical Center, (Riverside County Regional Medical Center) hereinafter referred to as COUNTY, and **Esoterix Genetic Laboratories, LLC**, hereinafter referred to as CONTRACTOR.

WHEREAS, Government Code Section 31000 authorizes the COUNTY to contract for special services to be provided by persons/entities who are specially trained, experienced and competent to perform the services required; and

WHEREAS, Contractor has the expertise, special skills, knowledge and experience to perform the duties set out herein;

NOW THEREFORE, in consideration of the mutual promises, covenants and conditions hereinafter contained the PARTIES hereto mutually agree as provided on pages 1 through 36, attached hereto and incorporated herein.

1.0 HIPAA Business Associate Agreement

The CONTRACTOR in this Agreement is subject to all relevant requirements contained in the Health Insurance Portability and Accountability Act of 1996 (HIPAA), Public Law 104-91, enacted August 21, 1996, and the laws and regulations promulgated subsequent thereto. CONTRACTOR indicates it is a covered entity and therefore, is not required to sign the COUNTY's HIPAA Business Associate Agreement as reflected in Attachment 1 attached hereto.

2.0 DESCRIPTION OF SERVICES

2.1 CONTRACTOR shall provide consultative services and perform specialized pathology testing to assist COUNTY in developing accurate diagnosis, prognosis and monitoring of patient's treatment.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

2.2 CONTRACTOR shall use its industry standard reasonable efforts to provide for slides and/or blocks to be returned within forty eight (48) hours after case completion.

2.3 CONTRACTOR shall during normal business hours (Monday through Friday, 8:00 a.m. to 5:00 p.m.), make available pathologists for phone consultation and trained customer service representatives to answer technical and logistical questions.

2.3.1 Inquiries requiring the medical / technical staff can be made through CONTRACTOR's Client Services departments at the following phone numbers, as may be updated from time to time:

- a) Reproductive / Genetics at **(800) 848-4436**.
- b) Oncology / Pathology at **(800) 447-5816**.

2.3.2 CONTRACTOR shall also provide an experienced trained account executive, known as a Territory Manager, as a point of contact for the COUNTY for the relevant field. The Territory Manager will be the communication liaison between the COUNTY and CONTRACTOR and responsible for coordinating and developing the relationship between the parties.

2.4 CONTRACTOR shall pick up / deliver specimens on a daily basis to COUNTY.

3.0 COUNTY RESPONSIBILITIES

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

3.1 COUNTY will provide CONTRACTOR, prior to or at the time of service, physician orders, patient information and any other documentation required to perform and bill for services under this agreement. COUNTY shall provide specimens to CONTRACTOR in accordance with CONTRACTOR's specimen requirements.

4.0 PERIOD OF PERFORMANCE

This Agreement shall be effective as of January 1, 2012 and continue in effect for twelve (12) months, with an option to renew (through mutually signed amendment) annually up to four (4) additional one-year terms, unless terminated as specified in Section 7.0 Termination.

5.0 COMPENSATION

5.1 Except as otherwise designated by COUNTY on the applicable test requisition form, CONTRACTOR shall invoice COUNTY for its services in accordance with **Exhibit A**, Payment Provisions, attached hereto and incorporated herein. Fees for services not listed in **Exhibit A** performed by CONTRACTOR at COUNTY's request will be invoiced and shall be paid by COUNTY at CONTRACTOR's list fees. Except as otherwise provided in this Section, this section may only be modified upon the written agreement of the parties hereto.

5.2 Maximum payments by COUNTY to CONTRACTOR shall not exceed three hundred seventy thousand dollars (\$370,000) annually including all expenses. The COUNTY is not responsible for any fees or costs incurred above or beyond the contracted amount and shall have no obligation to purchase any specified amount of services or products. Unless otherwise specifically stated in this Agreement,

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

COUNTY shall not be responsible for payment of any of CONTRACTOR's expense related to this Agreement.

5.3 No retroactive price adjustments will be considered. Any price increases must be stated in a written amendment to this Agreement.

5.4 All invoices submitted by CONTRACTOR shall be addressed to, Riverside County Regional Medical Center, Attention: Accounts Payable, 26520 Cactus Avenue, Moreno Valley, CA 92555.

5.5 COUNTY shall pay CONTRACTOR for services provided hereunder in accordance with the amounts invoiced within thirty (30) days of receipt of such invoice. This Section 5.5 shall survive termination of this Agreement.

6.0 ASSURANCES

6.1 CONTRACTOR agrees that, in the performance of services hereunder, it is, and will remain, in compliance with all applicable State and Federal laws and the applicable standards of CAP and CLIA.

6.2 CONTRACTOR certifies that it is aware of the Occupational Safety and Health Administration (OSHA) regulations of the U.S. Department of Labor, the derivative Cal/OSHA standards and laws and regulations relating thereto, and shall comply therewith as to all relative elements under this Agreement, as applicable.

7.0 TERMINATION

7.1 Each party may terminate this Agreement without cause upon 30 days written notice served upon the other party stating the extent and effective date of termination.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

7.2 Each party may, upon thirty (30) days written notice, terminate this Agreement for the other party's material breach of the terms and conditions of this Agreement and provided the breaching party does not cure such breach within such thirty (30) day notice period.

7.3 After receipt of the notice of termination, CONTRACTOR shall Stop all work under this Agreement on the date specified as the date of termination in the notice of termination; provided, however that CONTRACTOR can complete services requested by COUNTY that were in process as of the date of termination.

7.4 After termination, COUNTY shall make payment for CONTRACTOR's performance up to the date of termination as well as following termination with respect to any services that were in process as of the date of termination but completed after the date of termination, each in accordance with this Agreement and at the rates set forth herein. This Section 7.4 shall survive termination of this Agreement.

7.5 If either party terminates this Agreement prior to the end of the initial one-year term, then the parties shall not enter into any other type of agreement or arrangement with each other with respect to services covered by this Agreement prior to the date the initial term otherwise would have expired.

7.6 The rights and remedies of COUNTY provided in this section shall not be exclusive and are in addition to any other rights and remedies provided by law or this Agreement.

8.0 CONFIDENTIALITY

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

8.1 To the extent required by applicable laws, rules and regulations, CONTRACTOR agrees to protect from unauthorized disclosure of names and other identifying information concerning either persons receiving services under this Agreement or persons whose names or other identifying information becomes known to CONTRACTOR as a result of services performed under this Agreement, except statistical information not identifying any such person.

8.2 For the purpose of this paragraph, "identify" shall include, but not limited to, name, identifying number, symbol, or other identifying particular assigned to the individual, such as finger or voiceprint or photograph.

9.0 HOLD HARMLESS/INDEMNIFICATION

9.1 (a) CONTRACTOR shall indemnify, defend and hold harmless the County of Riverside, its directors, officers, elected and appointed officials, employees, agents and representatives (individually and collectively hereinafter referred to as COUNTY Indemnitees) from any liability whatsoever, incurred as a result of third party claims, demands, costs (including reasonable attorneys' fees) or judgments against or arising from injuries caused by the negligence or intentional wrongful act or omission by CONTRACTOR, its officers, employees, subcontractors, agents or representatives in the performance of this Agreement, including but not limited to property damage, bodily injury, or death or any other injury of any kind or nature whatsoever, unless liability is caused by or arises out of the negligence or intentional wrongful act or omission by any of the COUNTY Indemnitees.

(b) COUNTY shall be responsible for its own acts and omissions to the extent not prohibited pursuant to applicable laws, rules and regulations.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

9.2 The specified insurance limits required in this Agreement shall in no way limit or circumscribe CONTRACTOR'S obligations to indemnify and hold harmless the COUNTY Indemnitees herein from third party claims.

9.3 In the event there is conflict between this clause and California Civil Code Section 2782, this clause shall be interpreted to comply with Civil Code 2782. Such interpretation shall not relieve the CONTRACTOR or the COUNTY from their respective indemnification obligations hereunder, to the fullest extent allowed by law. This Article 9 shall survive termination of the Agreement.

9.4 Each party agrees to notify the other in writing promptly of receipt of notification of any claim made against either of them based on obligations indemnified against. However, failure to provide such notice shall not waive, reduce or otherwise affect in any way the obligations and rights of the parties hereunder unless such failure shall materially prejudice the ability of the indemnifying party to defend such claim.

10.0 INSURANCE

10.1 Without limiting or diminishing the CONTRACTOR'S obligation to indemnify or hold the COUNTY harmless, CONTRACTOR shall procure and maintain or cause to be maintained, at its sole cost and expense, the following insurance coverage's during the term of this Agreement.

10.2 WORKERS' COMPENSATION

If the CONTRACTOR has employees as defined by the State of California, the CONTRACTOR shall maintain statutory Workers' Compensation Insurance (Coverage A) as prescribed by the laws of the State of California. Policy shall include Employers' Liability (Coverage B) including Occupational Disease with limits not

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

less than **\$1,000,000** per person per accident. The policy shall be endorsed to waive subrogation in favor of The County of Riverside, and, if applicable, to provide a Borrowed Servant/Alternate Employer Endorsement.

10.3 COMMERCIAL GENERAL LIABILITY

Commercial General Liability insurance coverage, including but not limited to, contractual liability, covering claims which may arise from or out of CONTRACTOR'S performance of its obligations hereunder. Policy shall name the County of Riverside, its directors, officers, employees, elected or appointed officials, agents or representatives as Additional Insureds. Policy's limit of liability shall not be less than \$1,000,000 per occurrence combined single limit. If such insurance contains a general aggregate limit, it shall apply separately to this agreement or be no less than two (2) times the occurrence limit.

10.4 VEHICLE LIABILITY

If vehicles or mobile equipment are used in the performance of the obligations under this Agreement, then CONTRACTOR shall maintain liability insurance for all owned, non-owned or hired vehicles so used in an amount not less than \$1,000,000 per occurrence combined single limit. If such insurance contains a general aggregate limit, it shall apply separately to this agreement or be no less than two (2) times the occurrence limit.

10.5 PROFESSIONAL LIABILITY

CONTRACTOR shall maintain Professional Liability Insurance providing coverage for the CONTRACTOR's performance of work included within this Agreement, with a limit of liability of not less than **\$1,000,000** per occurrence and

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

\$2,000,000 annual aggregate. If CONTRACTOR's Professional Liability Insurance is written on a claims made basis rather than an occurrence basis, such insurance shall continue through the term of this Agreement and CONTRACTOR shall purchase at his sole expense either 1) an Extended Reporting Endorsement (also known as Tail Coverage); or 2) Prior Dates Coverage from new insurer with a retroactive date back to the date of, or prior to, the inception of this Agreement; or 3) demonstrate through Certificates of Insurance that CONTRACTOR has Maintained continuous coverage with the same or original insurer. Coverage provided under items; 1), 2) or 3) will continue for a period of five (5) years beyond the termination of this Agreement.

10.6 GENERAL INSURANCE PROVISIONS - ALL LINES

A. Any insurance carrier providing insurance coverage hereunder shall be admitted to the State of California and have an A M BEST rating of not less than A: VIII (A:8) unless such requirements are waived, in writing, by the County Risk Manager. If the County's Risk Manager waives a requirement for a particular insurer such waiver is only valid for that specific insurer and only for one policy term.

B. The CONTRACTOR'S insurance carrier(s) must declare its insurance deductibles or self-insured retentions. If such deductibles or self-insured retentions exceed \$500,000 per occurrence such deductibles and/or retentions shall have the prior written consent of the County Risk Manager before the commencement of operations under this Agreement. Upon notification of deductibles or self insured retention's unacceptable to the COUNTY, and at the election of the Country's Risk Manager, CONTRACTOR'S carriers shall either; 1) reduce or eliminate such

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

deductibles or self-insured retention's as respects this Agreement with the COUNTY, or

2) procure a bond which guarantees payment of losses and related investigations, claims administration, and defense costs and expenses.

C. CONTRACTOR shall cause CONTRACTOR'S insurance carrier(s) to furnish the County of Riverside with a properly executed original Certificate(s) of Insurance. In the event of a material modification, cancellation, expiration, or reduction in coverage, this Agreement shall terminate forthwith, unless the County of Riverside receives, prior to such effective date, another properly executed original Certificate of Insurance.

D. It is understood and agreed to by the parties hereto that the CONTRACTOR'S insurance shall be construed as primary insurance, and the COUNTY'S insurance and/or deductibles and/or self-insured retention's or self-insured programs shall not be construed as contributory.

E. if, during the term of this Agreement or any extension thereof, there is a material change in the scope of services; or, there is a material change in the equipment to be used in the performance of the scope of work which will add additional exposures (such as the use of aircraft, watercraft, cranes, etc.); or, the term of this Agreement, including any extensions thereof, exceeds five (5) years the COUNTY reserves the right to request adjustment to the types of insurance required under this Agreement and the monetary limits of liability for the insurance coverage's currently required herein, if; in the County Risk Manager's reasonable judgment, the amount or type of insurance carried by the CONTRACTOR has become inadequate;

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

provided, however that any modifications to CONTRACTOR's obligations must be mutually agreed in writing by the parties hereto.

F. CONTRACTOR shall pass down the insurance obligations contained herein to all tiers of subcontractors working under this Agreement.

G. The insurance requirements contained in this Agreement may be met with a program(s) of self-insurance acceptable to the COUNTY.

11.0 [Intentionally Omitted]

12.0 RECORDS AND DOCUMENTS

12.1 CONTRACTOR shall make available, upon written request by and duly authorized Federal, State or COUNTY agency, a copy of this Agreement and such books, documents and records as are necessary to certify the nature and extent of the costs of the services provided by CONTRACTOR to the extent required by 42 USC Section 1395x(v)(1)(I). All such CONTRACTOR shall maintain books and records for at least four (4) years from the termination of this Agreement.

12.2 CONTRACTOR to provide COUNTY with reports and information relative to this Agreement and in accordance with terms set forth herein, as may be reasonably requested by COUNTY.

13.0 MONITORING

CONTRACTOR hereby agrees to establish procedures for self-monitoring and shall permit an appropriate official of the COUNTY, State or Federal government to monitor, access, or evaluate CONTRACTOR'S performance under this Agreement; provided, however, that this shall not obligate CONTRACTOR to provide access to any CONTRACTOR facilities or records, except as otherwise set forth herein.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

14.0 LICENSE

14.1 CONTRACTOR shall, through the term of this Agreement, maintain all licenses necessary for the provision of the services hereunder and required by the applicable laws and regulations of the United States, the State of California, County of Riverside, and all other governmental agencies. Inability to obtain or maintain such license(s) shall be cause for termination of this Agreement.

14.2 CONTRACTOR shall ensure that CONTRACTOR'S employees, agents, and subcontractors performing services under the terms of this Agreement are in compliance with all applicable federal and state licensing requirements. Inability to obtain or maintain such license(s) shall be cause for termination of this Agreement.

14.3 COPY REQUIRED. Copies of CONTRACTOR's current licenses are available on its website (currently, at www.genzymegenetics.com)

14.4 Further, CONTRACTOR hereby agrees to abide by the applicable standards of medical practice of the profession when performing services hereunder.

15.0 NONDISCRIMINATION AND ELIGIBILITY

15.1 The CONTRACTOR shall not discriminate in the provision of services, allocation of benefits, accommodation in facilities, or employment of personnel, on the basis of ethnic group identification, race, color, creed, ancestry, religion, national origin, sexual preference, sex, age (over 40), marital status, or physical or mental handicap, and shall comply with all other applicable requirements of law regarding non discrimination and affirmative action including those laws pertaining to the prohibition of discrimination against qualified handicapped persons in all programs or activities.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

15.2 For the purpose of this Agreement, distinctions on the grounds of race, religion, color, sex, national origin, age, or physical or mental handicap include but are not limited to the following:

A. Denying an eligible person or providing to an eligible person any services or benefit which is different, or is provided in a different manner or at a different time from that provided to other eligible persons under this Agreement.

B. Treatment in any matter related to his receipt of any service, except when necessary for infection control.

C. Restricting an eligible person differently in any way in the enjoyment of any advantage or privilege enjoyed by others receiving similar service or benefit.

D. Treating an eligible person differently from others in determining whether he satisfied any eligibility, membership, or other requirement or condition which individuals must meet in order to be provided a similar service or benefit.

E. The assignment of times or places for the provision of services on the basis of race, religion, color, sex, national origin, age, or physical or mental handicap of the eligible person to be served.

16.0 CONFLICT OF INTEREST

In the performance of services pursuant to this Agreement, CONTRACTOR and CONTRACTOR'S employees shall follow the policies set forth in the Code of Conduct and Business Ethics of CONTRACTOR's parent, Laboratory

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

Corporation of America Holdings, which are designed to promote avoidance of conflicts of interests.

17.0 ALTERATION

17.1 No alteration or variation of the terms of this Agreement shall be valid unless made in writing and signed by the parties hereto, and no oral understanding or agreement not incorporated herein, shall be binding on any of the parties hereto.

17.2 Only the County Board of Supervisors or County Purchasing Agent may authorize the alteration or revision of this Agreement on behalf of the COUNTY. The parties expressly recognize that COUNTY personnel are without authorization to either change or waive any requirements of this Agreement.

18.0 ASSIGNMENT

CONTRACTOR may not delegate the obligations hereunder, either in whole or in part, without prior written consent of COUNTY provided, however, obligations undertaken by CONTRACTOR pursuant to this Agreement may be carried out by means of subcontracts if approved by COUNTY or may be delegated to an affiliate. No subcontract shall terminate or alter the responsibilities of the CONTRACTOR to COUNTY pursuant to this Agreement. CONTRACTOR may not assign the rights hereunder, either in whole or in part, without prior written consent of COUNTY; provided that CONTRACTOR may assign the rights hereunder to an affiliate without COUNTY's consent. Any attempted assignment or delegation in derogation of this paragraph shall be void. A change in the business structure of CONTRACTOR, including but not limited to, change in the majority ownership, change in the form of CONTRACTOR'S business organization, management of CONTRACTOR,

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

CONTRACTOR'S ownership of other business dealing with CONTRACTOR under this Agreement, or filing of bankruptcy by CONTRACTOR, shall be deemed an assignment for purposes of this paragraph.

19.0 ADMINISTRATION

The County of Riverside Laboratory Manager, or designee, shall administer this Agreement on behalf of the COUNTY. Contracts Administration is to serve as its liaison with CONTRACTOR in connection with this agreement.

20.0 WAIVER

Any waiver by a party hereto of any breach of any one or more of the terms of this Agreement shall not be construed to be a waiver of any subsequent or other breach of the same or of any other term thereof. Failure on the part of a party hereto to require exact, full and complete compliance by the other party hereto with any terms of this Agreement shall not be construed as in any manner changing the terms hereof or a waiver of enforcement hereof.

21.0 JURISDICTION, VENUE, SEVERABILITY

This Agreement and its construction and interpretation as to validity, performance and breach shall be construed under the laws of the State of California. Any legal action related to this Agreement shall be filed in the Superior Court of the State of California located in Riverside, California. In the event any provision in this Agreement is held by a court of competent jurisdiction to be invalid, void, or unenforceable, the remaining provisions will nevertheless continue in full force without being impaired or invalidated in any way.

22.0 INDEPENDENT CONTRACTOR

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

22.1 The CONTRACTOR is, for purposes arising out of this contract, an independent contractor and shall not be deemed an employee of the COUNTY. It is expressly understood and agreed that the CONTRACTOR shall in no event, as a result of this contract, be entitled to any benefits to which COUNTY employees are entitled, including but not limited to overtime, any retirement benefits, worker's compensation benefits, and injury leave or other leave benefits. CONTRACTOR hereby holds COUNTY harmless from any and all claims that may be made against COUNTY based upon any contention by any third party that an employer-employee relationship exists by reason of this agreement.

22.2 It is further understood and agreed by the parties hereto that CONTRACTOR in the performance of its obligation hereunder is subject to the control or direction of COUNTY merely as to the result to be accomplished by the services hereunder agreed to be rendered and performed and not as to the means and methods for accomplishing the results.

23.0 SUBCONTRACT FOR WORK OR SERVICES

23.1 No subcontract shall be made by the CONTRACTOR with any party for furnishing any of the work or services herein contained without the prior written approval of the COUNTY Contract Administrator but this provision shall not require the approval of contracts of employment between the CONTRACTOR and personnel assigned for services there under, or for parties named in the proposal and agreed to under any resulting contract.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

23.2 Should CONTRACTOR subcontract any services, CONTRACTOR shall obtain prior approval from COUNTY and shall require all subcontractors to abide by all the same terms and conditions stipulated in this master Contract Agreement. CONTRACTOR shall provide the name(s) of the subcontractor(s) and the portion of the work which will be subcontracted. Section 23.1 and the first two sentences of Section 23.2 shall not apply to (i) services performed by the parent or an affiliate of CONTRACTOR or (ii) performance by a third party of services requested by COUNTY of CONTRACTOR that are not within CONTRACTOR's directory of services. In the event services are requested by the COUNTY that are not within CONTRACTOR's directory of services, testing on a particular specimen may be performed by a third party laboratory and COUNTY shall reimburse CONTRACTOR for any such services at the rates charged to CONTRACTOR by such third party laboratory.

24.0 INTEREST OF CONTRACTOR

The CONTRACTOR presently has no interest, including but not limited to, other projects or independent contracts, and shall not acquire any such interest, direct or indirect, which would prevent the proper performance of services required to be performed under this contract.

25.0 CONFIDENTIALITY OF BUSINESS INFORMATION

25.1 Neither party hereto shall use for personal gain or make other improper use of privileged or confidential information of the other party, which is acquired in connection with this contract and each party shall take all responsible steps and do all things reasonably necessary to ensure any such privileged or confidential

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

information shall be kept confidential and shall not be disclosed or made use of except as necessary for the acquiring party to perform its obligations under this Agreement. In this connection, the term 'privileged information' includes, but is not limited to, unpublished information relating to technological and scientific development; pricing, names of clients, medical, personnel, or security records of the individuals; anticipated materials requirements or pricing actions; and knowledge of selection of CONTRACTOR or subcontractors in advance of official announcement.

25.2 The CONTRACTOR shall not under circumstances, which might reasonably be interpreted as an attempt to influence the recipient in the conduct of his duties, accept any gratuity or special favor from individuals or organizations with whom the CONTRACTOR is doing business or proposing to do business, in accomplishing the work under this contract.

25.3 The CONTRACTOR or employees thereof shall not offer gifts, gratuity, favors, and entertainment directly or indirectly to COUNTY employees.

26.0 RIGHT TO ACQUIRE EQUIPMENT AND SERVICES

Nothing in this agreement shall prohibit the COUNTY from acquiring the same type or equivalent equipment and/or service from other sources, when deemed by the COUNTY to be in its best interest.

27.0 FORCE MAJEURE

27.1 In the event CONTRACTOR is unable to comply with any provision of this agreement due to causes beyond their control such as acts of God, acts of war,

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

civil disorders, or other similar acts, CONTRACTOR shall not be held liable to COUNTY for such failure to comply.

27.2 In the event COUNTY is unable to comply with any provision of this agreement due to causes beyond its control relating to acts of God, acts of war, civil disorders, or other similar acts, COUNTY shall not be held liable to CONTRACTOR for such failure to comply.

28.0 CAPTIONS AND PARAGRAPH HEADINGS

Captions and paragraph headings used in this Agreement are for convenience only and are not a part of this Agreement and shall not be used in construing this Agreement.

29.0 NOTICES

All correspondence and notices required or contemplated by this Agreement shall be delivered to the respective parties at the addresses set forth below and are deemed submitted one day after their deposit in the United States mail, postage prepaid.

CONTRACTOR

Esoterix Genetic Laboratories, LLC
3400 Computer Drive
Westborough, MA 01581
Attn: Contract Administration

COUNTY

Riverside County Regional Medical Center
26520 Cactus Avenue
Moreno Valley, CA 92555
Attn: Contracts Administration

With a copy to:

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

Laboratory Corporation of America Holdings

531 S. Spring Street

Burlington, NC 27215

Attn: Law Department

30.0 RELEASE

Notwithstanding anything herein to the contrary, except for damages arising out of willful or reckless actions, neither party shall be liable to the other for indirect, incidental, consequential, exemplary, or special damages, including, without limitation, damages for lost profits, regardless of the form of action whether in contract, indemnity, warranty, strict liability, or tort.

31.0 DISCLAIMER OF WARRANTIES

Except as otherwise expressly provided in this Agreement; neither CONTRACTOR, nor any of its representatives or employees has made or makes any express or implied warranty to COUNTY. CONTRACTOR specifically disclaims the implied warranties of merchantability and fitness for a particular purpose.

32.0 ENTIRE AGREEMENT

This Agreement constitutes the entire agreement of the parties hereto with respect to its subject matter and supersedes all prior and contemporaneous representations, proposals, discussions and communications, whether oral or in writing. This contract may be modified only in writing and shall be enforceable in accordance with its terms when signed by each of the parties hereto.

**PROFESSIONAL SERVICES AGREEMENT
BETWEEN
RIVERSIDE COUNTY REGIONAL MEDICAL CENTER AND
ESOTERIX GENETIC LABORATORIES, LLC**

IN WITNESS WHEREOF, the parties have executed this Agreement.

CONTRACTOR

COUNTY

Esoterix Genetic Laboratories, LLC

By: 

Michael F. Minahan
Type or Print Name

Senior V.P. and General Manager,
Genzyme Genetics Business Unit
Type or Print Title

Date: 1/22/12

By: _____

Type or Print Name

Chairman
Type or Print Title

Date: _____

FORM APPROVED COUNTY COUNSEL
BY:  _____
NEAL R. RIPNIS DATE

1/26/12

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

The parties acknowledge and agree that the rates set forth herein constitute fair market value for the genetic testing services. The parties agree that COUNTY is under no obligation to solicit, refer or solicit referrals of patients for any CONTRACTOR business. COUNTY will not receive any benefit of any kind for making any referrals nor suffer any detriment for not making such referrals.

To the extent that the rates set forth below reflect a discount offered by CONTRACTOR, such discount may constitute a discount within the meaning of 42 U.S.C. §1320A-7b(b)(3)(A) of the Social Security Act, and may constitute a discount under similar state laws that are applicable to COUNTY. COUNTY may have an obligation to fully disclose and accurately report these discounts to state and federal programs which provide cost or charge based reimbursement for the services provided under the Agreement. COUNTY should retain the Agreement and any other price documentation and make them available to federal and state officials as may be required or upon request.

Exhibit A

Genetic Testing Fee Schedule

| | Test/ Profile | CPT4 | List Units | Client Discount Price |
|---|------------------|--------------|---------------|-----------------------------|
| Cytogenetics | | | | |
| Products of Conception Chromosome Analysis | 180 | | | \$ 460.00 |
| Tissue Culture for Non-neoplastic Disorders; Skin or other Solid Tissue Biopsy | | 88233 | 2 | |
| Chromosome Analysis; Count 15-20 Cells if possible, 2 Karyotypes, w/ Banding | | 88262 | 1 | |
| Cytogenetics & Molecular Cytogenetics, Interpretation and Report | | 88291 | 1 | |
| ONCOLOGY | | | | |
| IHC | | | | |
| Breast Cancer Profiles | | | | |
| ER/PR | 293 | | | \$ 200.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 2 | |
| ER/PR & HER2 FISH | 296 | | | \$ 500.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 2 | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 2 | |
| ER/PR, DNA, Her2 (FISH) | 612 | | | \$ 625.00 |
| Flow cytometry; cell cycle or DNA analysis | | 88182 | 1 | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 2 | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 2 | |
| ER/PR, DNA, Ki-67, Her2, Fish | 613 | | | \$ 625.00 |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|------------|---|--|------------------|
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 3 | | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | 88368 | 2 | | |
| ER/PR, DNA, Ki-67, P53, Her2, Fish | 614 | | | \$ 625.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 4 | | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | 88368 | 2 | | |
| Her2 FISH and Her2 by IHC | 611 | | | \$ 500.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 1 | | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | 88368 | 2 | | |
| ER/PR & Her2 - (IHC) | 294 | | | \$ 300.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 3 | | |
| ER/PR, Her2 (IHC) & Ki-67 | 295 | | | \$ 320.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 4 | | |
| ER/PR, DNA & Her2 (IHC) | 298 | | | \$ 225.00 |
| <i>Flow cytometry; cell cycle or DNA analysis</i> | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 3 | | |
| ER/PR, DNA, Ki-67 & Her2 (IHC) | 299 | | | \$ 225.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 4 | | |
| ER/PR, DNA, Ki-67, P53, Her2, IHC | 610 | | | \$ 450.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 5 | | |
| DNA & Ki-67 | 616 | | | \$ 195.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 1 | | |
| Individual Breast Cancer Markers | | | | |
| Her2 (IHC) | 290 | | | \$ 125.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | 1 | | |
| Her2 by FISH | 237 | | | \$ 400.00 |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|----------------|-------------|--------------|------------------|
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | 88368 | 2 | | |
| DNA | 420 | | | \$ 170.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Genetic Testing Fee Schedule | Test/ | CPT4 | List | Client |
| | Profile | | Units | Discount |
| | | | | Price |
| Colorectal Cancer Profiles | | | | |
| hMLH-1 / hMSH-2 by IHC | 664 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | 88342 | 2 | | |
| hMLH-1 / hMSH-2 / hMSH-6 by IHC | 665 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | 88342 | 3 | | |
| hMLH-1 / hMSH-2 / hMSH-6 / PMS2 by IHC | 666 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | 88342 | 4 | | |
| hMLH-1 / hMSH-2 by IHC & MSI by PCR | 668 | | | \$ 900.00 |
| Molecular Diagnostics; Molecular Isolation or Extraction | 83890 | 2 | | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | 8 | | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | 1 | | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | 83909 | 2 | | |
| Interpretation and Report Professional Component | 83912-26 | 1 | | |
| Immunohistochemistry, Each Antibody | 88342 | 2 | | |
| Microdissection; Manual | 88381 | 1 | | |
| IHC | | | | |
| hMLH-1 / hMSH-2 / hMSH-6 by IHC & MSI by PCR | 669 | | | \$ 950.00 |
| Molecular Diagnostics; Molecular Isolation or Extraction | 83890 | 2 | | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | 8 | | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | 1 | | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | 83909 | 2 | | |
| Interpretation and Report Professional Component | 83912-26 | 1 | | |
| Immunohistochemistry, Each Antibody | 88342 | 3 | | |
| Microdissection; Manual | 88381 | 1 | | |

Colorectal Cancer Profiles (Continued)

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|-----------------|--|---|--------------------|
| hMLH-1 / hMSH-2 / hMSH-6 / PMS2 by IHC & MSI by PCR | 659 | | | \$ 1,000.00 |
| Molecular Diagnostics; Molecular Isolation or Extraction | 83890 | | 2 | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | | 1 | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | | 8 | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | 83909 | | 2 | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | | 1 | |
| Interpretation and Report Professional Component | 83912-26 | | 1 | |
| Immunohistochemistry, Each Antibody | 88342 | | 4 | |
| Microdissection; Manual | 88381 | | 1 | |
| p53 & TS | 660 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | 88342 | | 1 | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 1 | |
| p27, p53 & TS | 661 | | | \$ 225.00 |
| Immunohistochemistry, Each Antibody | 88342 | | 1 | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 2 | |
| p53, TS & DNA | 662 | | | \$ 500.00 |
| Immunohistochemistry, Each Antibody | 88342 | | 1 | |
| Flow cytometry; cell cycle or DNA analysis | 88182 | | 1 | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 1 | |
| p27, p53, TS & DNA | 663 | | | \$ 395.00 |
| Immunohistochemistry, Each Antibody | 88342 | | 1 | |
| Flow cytometry; cell cycle or DNA analysis | 88182 | | 1 | |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 2 | |
| Colorectal Cancer IHC Individual Markers | | | | |
| IHC (hMLH1/hMSH2/hMSH6/PMS2) | 671 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | 88342 | | 1 | |
| IHC Prognostic/Predictive (TS/EGFR/P27/P53) | 678 | | | \$ 125.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 1 | |
| EGFR (Pharm DX) IHC | 670 | | | \$ 200.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 1 | |
| ERCC1 Analysis | 604 | | | \$ 200.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | 88360 | | 1 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|--|----------------|-------------|--------------|-----------------|
| DNA - Colorectal | 435 | | | \$ 210.00 |
| Flow Cytometry; Cell Cycle or DNA Analysis | | 88182 | 1 | |
| Genetic Testing Fee Schedule | Test/ | CPT4 | List | Client |
| | Profile | | Units | Discount |
| | | | | Price |
| Diagnostic IHC | | | | |
| IHC (Immunohistochemistry) Technical Component Only | 675 | | | \$ 45.00 |
| Technical component; Immunohistochemistry, Each Antibody | | 88342-TC | 1 | |
| IHC (Immunohistochemistry) Technical Component Only | 676 | | | \$ 60.00 |
| Technical Component; Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360-TC | 1 | |
| IHC Prognostic/Predictive (TS/EGFR/P27/P53) | 678 | | | \$ 125.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 1 | |
| Immunohistochemistry (1) | 690 | | | \$ 60.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 1 | |
| Immunohistochemistry (2) | 691 | | | \$ 120.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 2 | |
| Immunohistochemistry (3) | 692 | | | \$ 180.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 3 | |
| Immunohistochemistry (4) | 693 | | | \$ 350.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 4 | |
| Refer to Antibody Library of >200 IHC markers | 674 | | | \$ 50.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 1 | |
| Immunohistochemistry Quantitative or Semiquantitative (1) | 694 | | | \$ 60.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 1 | |
| Immunohistochemistry Quantitative or Semiquantitative (2) | 695 | | | \$ 120.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 2 | |
| Immunohistochemistry Quantitative or Semiquantitative (3) | 696 | | | \$ 180.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 3 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|------------|-----------------|----------|------------------|
| Immunohistochemistry Quantitative or Semiquantitative (4) | 697 | | | \$ 320.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 4 | |
| IHC Prognostic/Predictive Markers (ER/PR/Ki-67/p53) | 678 | | | \$ 125.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody, Manual | | 88360 | 1 | |
| Micrometastases | | | | |
| Bone Marrow/ Peripheral Blood Micrometastases Fresh (single antibody) | 631 | | | \$ 200.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 1 | |
| Melanoma-Micrometastases- Lymph Node (two antibodies) | 632 | | | \$ 215.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 2 | |
| Molar Pregnancy Evaluation | | | | |
| Molar Pregnancy Evaluation (p57 and DNA Ploidy/ S Phase) | 677 | | | \$ 195.00 |
| Immunohistochemistry, Each Antibody | | 88342 | 1 | |
| Flow cytometry; cell cycle or DNA analysis | | 88182 | 1 | |
| iSCOPE | | | | |
| ER/PR (iSCOPE) Global | 255 | | | \$ 340.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody; Using Computer Assisted Technology | | 88361 | 2 | |
| ER/PR (iSCOPE) Technical Component Only | 256 | | | \$ 225.00 |
| Technical Component;Morphometric analysis, Tumor | | 88361-TC | 2 | |
| Her2 (iSCOPE) Global | 257 | | | \$ 150.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody; Using Computer Assisted Technology | | 88361 | 1 | |
| Her2 (iSCOPE) Technical Component Only | 258 | | | \$ 100.00 |
| Technical Component;Morphometric analysis, Tumor | | 88361-TC | 1 | |
| Ki-67 (iSCOPE) Global | 259 | | | \$ 40.00 |
| Morphometric Analysis, Tumor Immunohistochemistry Quantitative or Semiquantitative, Each Antibody; Using Computer Assisted Technology | | 88361 | 1 | |
| Ki-67 (iSCOPE) Technical Component Only | 260 | | | \$ 25.00 |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| Genetic Testing Fee Schedule | Test/ Profile | 88361- TC CPT4 | List Units | Client Discount Price |
|--|------------------|----------------------|---------------|-----------------------------|
| Technical Component; Morphometric analysis, Tumor | | 88361- TC | 1 | |
| Bone Marrow Morphology | | | | |
| Complete Bone Marrow Morphology Study: includes BM aspirate | 680 | | | \$ 460.00 |
| Bone Marrow, Smear Interpretation | | 85097 | 1 | |
| Level IV - Surgical Pathology, Gross and Microscopic Examination | | 88305 | 1 | |
| Decalcification Procedure | | 88311 | 1 | |
| Special Stains, Group II, All other except Immunocytochemistry | | 88313 | 3 | |
| Special Stains - Group II | 681 | | | \$ 80.00 |
| Special Stains, Group II, All other except Immunocytochemistry | | 88313 | 1 | |
| Special Stain- Group I for microorganisms | 682 | | | \$ 80.00 |
| Special Stains, Group I for Microorganisms, Each | | 88312 | 1 | |
| Determinative Histochemistry | 683 | | | \$ 80.00 |
| Determinative Histochemistry or Cytochemistry to Identify Enzyme | | 88319 | 1 | |
| Genetic Testing Fee Schedule | | | | |
| Bone Marrow Smear Interpretation | 684 | | | \$ 280.00 |
| Bone Marrow, Smear Interpretation | | 85097 | 1 | |
| Peripheral Blood Smear Interpretation | 685 | | | \$ 200.00 |
| Blood Smear, Peripheral, Interpretation by Physician with Written Report | | 85060 | 1 | |
| Special Stains - Group II | 686 | | | \$ 138.00 |
| Technical Component; Special Stains, Group II | | 88313- TC | 1 | |
| Special Stains - Group I for microorganisms | 687 | | | \$ 132.00 |
| Technical Component; Special Stains, Group 1 | | 88312- TC | 1 | |
| Submitted Stained Slide | 688 | | | \$ 200.00 |
| Professional Component; Special Stains, Group II | | 88313- 26 | 1 | |
| Decalcification Procedure | 689 | | | \$ 70.00 |
| Decalcification Procedure | | 88311 | 1 | |
| Pathology consultation and report on referred slides | 426 | | | \$ 375.00 |
| Consultation and Report on Referred Slides Prepared Elsewhere | | 88321 | 1 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|--|------------|-----------------|----|--------------------|
| Pathology Review | 429 | | | \$ 276.00 |
| Level IV - Surgical Pathology, Gross and Microscopic Examination | | 88305 | 1 | |
| Determinative Histochemistry - Technical Component | 698 | 88319-TC | 1 | \$ 276.00 |
| Flow Cytometry | | | | |
| Comprehensive Screening Panel | 451 | | | \$ 400.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 23 | |
| Flow Cytometry, Interpretation, 16 or more Markers | | 88189 | 1 | |
| CLL Panel | 453 | | | \$ 400.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 17 | |
| Flow Cytometry, Interpretation, 16 or more Markers | | 88189 | 1 | |
| Lymphoma -Tissue/Fluid Panel | 411 | | | \$ 400.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 18 | |
| Flow Cytometry, Interpretation, 16 or more Markers | | 88189 | 1 | |
| Plasma Cell Panel | 455 | | | \$ 400.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 16 | |
| Flow Cytometry, Interpretation, 16 or more Markers | | 88189 | 1 | |
| PNH Panel | 417 | | | \$ 395.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 3 | |
| Flow Cytometry, Interpretation, 2 to 8 Markers | | 88187 | 1 | |
| ZAP 70 Expression (Prior CLL Diagnosis) | 415 | | | \$ 395.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | | 88185 | 3 | |
| Flow Cytometry, Interpretation, 2 to 8 Markers | | 88187 | 1 | |
| Flow Cytometry: CLL-MRD | 419 | | | \$ 1,000.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | | 88184 | 1 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|--|--------------------------|-------------|-----------------------|--------------------------------------|
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 11 | | |
| Flow Cytometry, Interpretation, 9 to 15 Markers | 88188 | 1 | | |
| Flow Cytometry First Marker | 430 | | | \$ 85.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | 88184 | 1 | | |
| Flow Cytometry Each Additional Marker | 431 | | | \$ 75.00 |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 1 | | |
| Genetic Testing Fee Schedule | | | | |
| | Test/ Profile | CPT4 | List Units | Client Discount Price |
| Flow Cytometry (Continued) | | | | |
| Flow Cytometry Interpretation; (2-8 markers) | 432 | | | \$ 100.00 |
| Flow Cytometry, Interpretation, 2 to 8 Markers | 88187 | 1 | | |
| Flow Cytometry Interpretation; (9-15 markers) | 433 | | | \$ 150.00 |
| Flow Cytometry, Interpretation, 9 to 15 Markers | 88188 | 1 | | |
| Flow Cytometry Interpretation; (16 or more markers) | 434 | | | \$ 160.00 |
| Flow Cytometry, Interpretation, 16 or more Markers | 88189 | 1 | | |
| DNA | 420 | | | \$ 170.00 |
| Flow cytometry; cell cycle or DNA analysis | 88182 | 1 | | |
| Interactive Flow Cytometry | | | | |
| CLL Panel | 454 | | | \$ 395.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | 88184 | 1 | | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 17 | | |
| Comprehensive Screening Panel | 452 | | | \$ 375.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | 88184 | 1 | | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 23 | | |
| Lymphoma -Tissue/Fluid Panel (TF) | 407 | | | \$ 375.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | 88184 | 1 | | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 18 | | |
| Plasma Cell Panel | 456 | | | \$ 375.00 |
| Flow Cytometry, Cell Surface, Cytoplasmic, or Nuclear Marker, Technical Component only, First Marker | 88184 | 1 | | |
| Flow Cytometry, Each Additional Marker (list separately in addition to code for first marker) | 88185 | 16 | | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| Cytogenetics | | | | | |
|---|------------|--------------|---|-----------|---------------|
| Chromosome Analysis, Bone Marrow | 130 | | | \$ | 460.00 |
| Tissue Culture for Neoplastic Disorders; Bone Marrow, | | 88237 | 2 | | |
| Chromosome Analysis; Count 15-20 Cells if possible, 2 | | 88262 | 1 | | |
| Karyotypes, w/ Banding | | | | | |
| Cytogenetics & Molecular Cytogenetics, Interpretation and Report | | 88291 | 1 | | |
| Chromosome Analysis, Leukemic Blood | 170 | | | \$ | 460.00 |
| Tissue Culture for Neoplastic Disorders; Bone Marrow, | | 88237 | 2 | | |
| Chromosome Analysis; Count 15-20 Cells if possible, 2 | | 88262 | 1 | | |
| Karyotypes, w/ Banding | | | | | |
| Cytogenetics & Molecular Cytogenetics, Interpretation and Report | | 88291 | 1 | | |
| Chromosome Analysis, Solid Tumor/ Lymphnode/ Ascites/ Effusion | 171 | | | \$ | 460.00 |
| Tissue Culture for Neoplastic Disorders; Solid Tumor | | 88239 | 2 | | |
| Chromosome Analysis; Count 15-20 Cells if possible, 2 | | 88262 | 1 | | |
| Karyotypes, w/ Banding | | | | | |
| Cytogenetics & Molecular Cytogenetics, Interpretation and Report | | 88291 | 1 | | |
| Set-up Fee: Unsuccessful Culture/Cancelled Test: Solid Tumor | 760 | 88239 | 2 | \$ | 75.00 |
| Set-up Fee: Unsuccessful Culture/Cancelled Test: Neoplastic | 730 | 88237 | 2 | \$ | 75.00 |
| Tissue Culture for Neoplastic Disorders; Solid Tumor | 188 | 88239 | 2 | \$ | 166.00 |
| Tissue Culture for Neoplastic Disorders; Bone Marrow, Blood Cells | 192 | 88237 | 2 | \$ | 166.00 |
| FISH Hematology/Oncology | | | | | |
| When requested, Fluorescence In Situ Hybridization (FISH) can be performed as an adjunct to a Genzyme Genetics cytogenetic study. | | | | | |
| Interphase FISH Analyze 100-300 Cells | | | | | |
| One Probe, One Hybridization / Analysis | 461 | | | \$ | 250.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 1 | | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 1 | | |
| Individual FISH Probe (Oncology) | 463 | | | \$ | 56.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 1 | | |
| Two Probes, Two Hybridizations / Analyses | 466 | | | \$ | 320.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 2 | | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 2 | | |
| Three Probes, Three Hybridizations / Analyses | 467 | | | \$ | 360.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 3 | | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 3 | | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|----------------|--------------|-------|--------------------|
| Four Probes, Four Hybridizations / Analyses | 468 | | | \$ 400.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 4 | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 4 | |
| Five Probes, Five Hybridizations / Analyses | 469 | | | \$ 480.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 5 | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 5 | |
| Six Probes, Six Hybridizations / Analyses | 464 | | | \$ 560.00 |
| Molecular Cytogenetics, DNA Probe Each | | 88271 | 6 | |
| Interphase in situ Hybridization, Analyze 100-300 Cells | | 88275 | 6 | |
| Genetic Testing Fee Schedule | Test/ | CPT4 | List | Client |
| | Profile | | Units | Discount |
| | | | | Price |
| FISH Hematology/Oncology (Continued) | | | | |
| When requested, Fluorescence In Situ Hybridization (FISH) can be performed as an adjunct to a Genzyme Genetics cytogenetic study. | | | | |
| Metaphase FISH, Analyze 10-30 Cells | | | | |
| Interpretation and Report Added to all Interphase or Metaphase FISH | | | | |
| Cytogenetics & Molecular Cytogenetics, Interpretation & Report | 465 | 88291 | 1 | \$ 66.00 |
| clg Staining | 441 | | | \$ 280.00 |
| Immunofluorescent study, each antibody; indirect method | | 88347 | 1 | |
| clg FISH Multiple Myeloma Profile | 442 | | | \$ 1,868.00 |
| Immunofluorescent study, each antibody; indirect method | | 88347 | 1 | |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 6 | |
| clg FISH Individual Probes | 443 | | | \$ 397.00 |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 1 | |
| FISH Solid Tumor | | | | |
| EGFR by FISH | 679 | | | \$ 700.00 |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 2 | |
| Her2 by FISH | 237 | | | \$ 400.00 |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 2 | |
| UROVYSION (LA Lab) | 486 | | | \$ 400.00 |
| Morphometric Analysis, in situ Hybridization Quantitative or Semiquantitative, Each Probe, Manual | | 88368 | 4 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| ISH | | | | |
|--|------------|-----------------|----------|------------------|
| EBER (Epstein Barr Virus) | 774 | | | \$ 100.00 |
| In situ Hybridization (eg, FISH), Each Probe | | 88365 | 1 | |
| HPV Screen | 770 | | | \$ 125.00 |
| In situ Hybridization (eg, FISH), Each Probe | | 88365 | 1 | |
| HPV Screen & Subtype | 771 | | | \$ 250.00 |
| In situ Hybridization (eg, FISH), Each Probe | | 88365 | 4 | |
| HPV Subtype Only | 772 | | | \$ 125.00 |
| In situ Hybridization (eg, FISH), Each Probe | | 88365 | 3 | |
| ISH - Technical Component Only | 775 | | | \$ 180.00 |
| Technical Component In situ Hybridization (eg, FISH), each probe | | 88365-TC | 1 | |
| PML (JC Virus) | 773 | | | \$ 100.00 |
| In situ Hybridization (eg, FISH), Each Probe | | 88365 | 1 | |
| Molecular | | | | |
| ABL Kinase Mutation analysis in CML | 151 | | | \$ 787.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | | 83891 | 1 | |
| Enzymatic Digestion | | 83892 | 2 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 6 | |
| Reverse Transcription | | 83902 | 1 | |
| Mutation ID by Sequencing Single Segment, Each Segment | | 83904 | 2 | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | | 83909 | 2 | |
| Interpretation and Report | | 83912 | 1 | |
| AML/ETO by PCR - t(8;21) | 308 | | | \$ 250.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | | 83891 | 1 | |
| Enzymatic Digestion | | 83892 | 1 | |
| Nucleic Acid Probe, Each | | 83896 | 2 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 2 | |
| Reverse Transcription | | 83902 | 2 | |
| Interpretation and Report Professional Component | | 83912-26 | 1 | |
| B-Cell Gene Rearrangements by PCR | 165 | | | \$ 391.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | | 83891 | 1 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 3 | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | | 83909 | 3 | |
| Interpretation and Report | | 83912 | 1 | |
| EGFR Mutation Tumor Analysis | 163 | | | \$ 800.00 |
| Molecular Diagnostics; Molecular Isolation or Extraction | | 83890 | 1 | |
| Enzymatic Digestion | | 83892 | 4 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 4 | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|------------|----------------|-------------|------------------------------|
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | 2 | | |
| Mutation ID by Sequencing Single Segment, Each Segment | 83904 | 8 | | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | 1 | | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | 83909 | 8 | | |
| Interpretation and Report | 83912 | 1 | | |
| Microdissection; Manual | 88381 | 1 | | |
| Genetic Testing Fee Schedule | | Test/ | CPT4 | List |
| | | Profile | | Units |
| Molecular (Continued) | | | | Client Discount Price |
| IgVH Mutation Analysis | 318 | | | \$ 1,000.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Enzymatic Digestion | 83892 | 2 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | 12 | | |
| Reverse Transcription | 83902 | 1 | | |
| Mutation ID by Sequencing Single Segment, Each Segment | 83904 | 1 | | |
| Separation and Identification by High Resolution Technique (eg. capillary electrophoresis) | 83909 | 1 | | |
| Interpretation and Report | 83912 | 1 | | |
| Inv (16) RT - PCR | 168 | | | \$ 293.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Enzymatic Digestion | 83892 | 1 | | |
| Nucleic Acid Probe, Each | 83896 | 1 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 1 | | |
| Reverse Transcription | 83902 | 1 | | |
| Interpretation and Report Professional Component | 83912-26 | 1 | | |
| JAK2 V617F Mutation | 317 | | | \$ 225.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Enzymatic Digestion | 83892 | 1 | | |
| Nucleic Acid Probe, Each | 83896 | 2 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 1 | | |
| Interpretation and Report | 83912 | 1 | | |
| KRAS Mutation Analysis | 177 | | | \$ 587.88 |
| Molecular Diagnostics; Molecular Isolation or Extraction | 83890 | 1 | | |
| Enzymatic Digestion | 83892 | 3 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 1 | | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | 1 | | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|--|--------------|---|-----------|---------------|
| Separation and Identification by High Resolution Technique (eg.capillary electrophoresis) | 83909 | 2 | | |
| Interpretation and Report | 83912 | 1 | | |
| Mutation ID by Enzymatic Ligation or Primer Extension, Single Segment, Each Segment | 83914 | 4 | | |
| Microdissection; Manual | 88381 | 1 | | |
| <hr/> | | | | |
| Microsatellite Instability by PCR (MSI) | 672 | | \$ | 325.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 2 | | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional Nucleic Acid Sequence | 83901 | 8 | | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | 83907 | 1 | | |
| Separation and Identification by High Resolution Technique (eg.capillary electrophoresis) | 83909 | 2 | | |
| Interpretation and Report Professional Component | 83912- 26 | 1 | | |
| Microdissection; Manual | 88381 | 1 | | |
| <hr/> | | | | |
| P53 Mutation Analysis | 304 | | \$ | 683.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 3 | | |
| Enzymatic Digestion | 83892 | 2 | | |
| Separation and Identification by High Resolution Technique (eg.capillary electrophoresis) | 83909 | 3 | | |
| Mutation ID by Sequencing Single Segment, Each Segment | 83904 | 3 | | |
| Interpretation and Report | 83912 | 1 | | |
| <hr/> | | | | |
| PML / RARA by PCR - t(15;17) | 307 | | \$ | 250.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Enzymatic Digestion | 83892 | 1 | | |
| Nucleic Acid Probe, Each | 83896 | 3 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 2 | | |
| Reverse Transcription | 83902 | 1 | | |
| Interpretation and Report Professional Component | 83912- 26 | 1 | | |
| <hr/> | | | | |
| Quantitative BCR-ABL RT-PCR | 159 | | \$ | 600.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 2 | | |
| Nucleic Acid Probe, Each | 83896 | 8 | | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83898 | 8 | | |
| Reverse Transcription | 83902 | 2 | | |
| Interpretation and Report | 83912 | 1 | | |
| Enzymatic Digestion | 83892 | 2 | | |
| <hr/> | | | | |
| T-Cell Gene Rearrangements by PCR | 166 | | \$ | 400.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, First Two Nucleic Acid Sequences | 83900 | 1 | | |
| Amplification of Patient Nucleic Acid, Multiplex, Each Additional | 83901 | 8 | | |

**PAYMENT PROVISION
ESOTERIX GENETIC LABORATORIES, LLC**

| | | | | |
|---|--------------------------|--------------|-----------------------|--------------------------------------|
| Nucleic Acid Sequence Separation and Identification by High Resolution Technique (eg.capillary electrophoresis) | 83909 | 4 | | |
| Interpretation and Report | 83912 | 1 | | |
| UGT1A1 | 158 | | | \$ 700.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | 83891 | 1 | | |
| Enzymatic Digestion | 83892 | 8 | | |
| Nucleic Acid Probe, Each | 83896 | 12 | | |
| Signal Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | 83908 | 4 | | |
| Interpretation and Report | 83912 | 1 | | |
| Genetic Testing Fee Schedule | | | | |
| | Test/ Profile | CPT4 | List Units | Client Discount Price |
| Pathologist Consultation | | | | |
| Comprehensive Pathology Consultation and Report (may include IHC) | 425 | | | \$ 250.00 |
| Consultation and Report on Referred Material Requiring Preparation of Slides | | 88323 | 1 | |
| Comprehensive Pathology Consultation and Report on referred slides | 426 | | | \$ 375.00 |
| Consultation and Report on Referred Slides Prepared Elsewhere | | 88321 | 1 | |
| CMBP-YU Oncology (919) 361-7700 | | | | |
| BRAF Gene Mutation Detection | 2015 | | | \$ 290.00 |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | | 83907 | 1 | |
| Isolation or Extraction of Highly Purified Nucleic Acids | | 83891 | 1 | |
| Nucleic Acid Probe, Each | | 83896 | 2 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 2 | |
| Interpretation and Report | | 83912 | 1 | |
| BRAF Gene Mutation Detection, Melanoma | 480450 | | | \$ 550.00 |
| Isolation or Extraction of Highly Purified Nucleic Acids | | 83891 | 1 | |
| Nucleic Acid Probe, Each | | 83896 | 1 | |
| Amplification of Patient Nucleic Acid, Each Nucleic Acid Sequence | | 83898 | 1 | |
| Lysis of Cells Prior to Nucleic Acid Extraction (eg, stool specimens, paraffin embedded tissue) | | 83907 | 1 | |
| Interpretation and Report | | 83912 | 1 | |
| Professional Component;Microdissection; Manual | | 88381- 26 | 1 | |
| Technical Component;Microdissection; Manual | | 88381- TC | 1 | |

HIPAA BUSINESS ASSOCIATE AGREEMENT
Between the County of Riverside and
ESOTERIX GENETIC LABORATORIES, LLC

CONTRACTOR indicates it is a covered entity and therefore, is not required to sign COUNTY's HIPAA Business Associate Agreement.